A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.

Vincent Chung,Erkut Borazanci,Gayle S. Jameson,Ronald M. Evans,Michael Downes,Morgan Truitt,Hitendra Patel,Andrew M. Lowy,Denise J. Roe,Karen Ansaldo,Michael T. Barrett,Ronald L. Korn,Lana Caldwell,Gavin Slethaug,Rolf Hultsch,Haiyong Han,David M. Engelthaler,Talima R Pearson,Elizabeth Lenkiewics,Daniel D. Von Hoff

A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.

2018

TPS4154Background: Pancreatic cancer remains a deadly disease and despite advances in chemotherapy treatment, survival for most patients is still less than one year. Refractory pancreatic cancer ha...

Keywords:

Paricalcitol
Urology
Pathology
Stage IV Pancreatic Cancer
Pembrolizumab
Medicine
Pancreatic cancer
in patient
Refractory
Chemotherapy
Oncology
Internal medicine
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations